Authors' Affiliation: Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Clin Cancer Res. 2013 Sep 15;19(18):4908-10. doi: 10.1158/1078-0432.CCR-13-1540. Epub 2013 Aug 7.
Prostate cancer has a highly tumor-restricted prostate-specific membrane antigen (PSMA) and may be the ideal solid-organ malignancy for treatment with radioimmunotherapy. Encouraging results using lutetium-177-labeled anti-PSMA monoclonal antibody J591 from a phase II study by Tawaga and colleagues support the continued clinical and preclinical development of radioimmunotherapy for solid tumors.
前列腺癌具有高度肿瘤受限的前列腺特异性膜抗原（PSMA），因此可能是用放射性免疫疗法治疗的理想实体恶性肿瘤。Tawaga 及其同事进行的 II 期研究中使用镥-177 标记的抗 PSMA 单克隆抗体 J591 获得了令人鼓舞的结果，这支持了放射性免疫疗法用于实体瘤的临床和临床前开发的持续进行。
